drugset / Trial / NCT05316116
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
Phase 0
Terminated
6 enrolled
H. Lee Moffitt Cancer Center and Research Institute
EUSA Pharma, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia (LGLL).
Timeline
- Start
- 2023-02-15
- Primary completion
- 2024-10-18
- Completion
- 2024-10-18
Outcome
Outcome not reported
Stopped: “lack of efficacy/futility”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siltuximab | Monoclonal antibody | 11 mg/kg | Intravenous |